Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
NUTRAPLUS PR TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
NUTRAPLUS PR Mar-20 |
TEVA PHARMA Dec-13 |
NUTRAPLUS PR/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 22 | 3,484 | - | |
Low | Rs | 5 | 3,027 | - | |
Sales per share (Unadj.) | Rs | 25.6 | 1,999.5 | - | |
Earnings per share (Unadj.) | Rs | -14.0 | 124.9 | - | |
Cash flow per share (Unadj.) | Rs | -12.7 | 286.5 | - | |
Dividends per share (Unadj.) | Rs | 0 | 109.35 | - | |
Avg Dividend yield | % | 0 | 3.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 6.3 | 2,221.1 | - | |
Shares outstanding (eoy) | m | 34.09 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 0.5 | 1.6 | 32.7% | |
Avg P/E ratio | x | -1.0 | 26.1 | -3.7% | |
P/CF ratio (eoy) | x | -1.1 | 11.4 | -9.5% | |
Price / Book Value ratio | x | 2.1 | 1.5 | 146.6% | |
Dividend payout | % | 0 | 87.5 | -0.0% | |
Avg Mkt Cap | Rs m | 464 | 2,760,520 | 0.0% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 73 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,726.3 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,356.7 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 873 | 1,695,610 | 0.1% | |
Other income | Rs m | 1 | 0 | - | |
Total revenues | Rs m | 875 | 1,695,610 | 0.1% | |
Gross profit | Rs m | -358 | 464,344 | -0.1% | |
Depreciation | Rs m | 47 | 137,058 | 0.0% | |
Interest | Rs m | 74 | 33,305 | 0.2% | |
Profit before tax | Rs m | -478 | 293,981 | -0.2% | |
Minority Interest | Rs m | 0 | 1,336 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,983 | -0.0% | |
Tax | Rs m | 0 | -3,589 | -0.0% | |
Profit after tax | Rs m | -478 | 105,923 | -0.5% | |
Gross profit margin | % | -41.0 | 27.4 | -149.8% | |
Effective tax rate | % | 0 | -1.2 | 0.0% | |
Net profit margin | % | -54.8 | 6.2 | -876.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 178 | 1,145,208 | 0.0% | |
Current liabilities | Rs m | 890 | 998,719 | 0.1% | |
Net working cap to sales | % | -81.5 | 8.6 | -943.5% | |
Current ratio | x | 0.2 | 1.1 | 17.4% | |
Inventory Days | Days | 1 | 91 | 0.7% | |
Debtors Days | Days | 11,562,625 | 96 | 12,055,367.1% | |
Net fixed assets | Rs m | 939 | 553,823 | 0.2% | |
Share capital | Rs m | 170 | 4,174 | 4.1% | |
Net worth | Rs m | 216 | 1,883,501 | 0.0% | |
Long term debt | Rs m | 2 | 867,003 | 0.0% | |
Total assets | Rs m | 1,117 | 3,875,011 | 0.0% | |
Interest coverage | x | -5.4 | 9.8 | -55.3% | |
Debt to equity ratio | x | 0 | 0.5 | 2.1% | |
Sales to assets ratio | x | 0.8 | 0.4 | 178.8% | |
Return on assets | % | -36.2 | 3.6 | -1,006.9% | |
Return on equity | % | -221.3 | 5.6 | -3,934.6% | |
Return on capital | % | -185.1 | 4.9 | -3,754.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 91 | 270,192 | 0.0% | |
From Investments | Rs m | -27 | -95,740 | 0.0% | |
From Financial Activity | Rs m | -76 | -324,114 | 0.0% | |
Net Cashflow | Rs m | -12 | -149,662 | 0.0% |
Compare NUTRAPLUS PR With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US)
Compare NUTRAPLUS PR With: VEERHEALTH CARE ISHITA DRUGS CONCORD DRUGS LAURUS LABS SHUKRA PHARMA
Asian stocks got off to a shaky start on Thursday after the Federal Reserve flagged delays to interest rate cuts, while the dollar fell heavily on the yen in what traders reckoned was Japanese intervention.